MENU
BAX
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

BAX stock forecast, quote, news & analysis

Baxter offers a variety of medical supplies and equipment to providers... Show more

BAX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for BAX with price predictions
Sep 11, 2026

BAX in upward trend: price may jump up because it broke its lower Bollinger Band on September 08, 2026

BAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 42 cases where BAX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BAX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 165 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAX as a result. In 58 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for BAX turned negative on August 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 33 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

BAX moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

The Aroon Indicator for BAX entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.983) is normal, around the industry mean (4.965). P/E Ratio (87.846) is within average values for comparable stocks, (142.488). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (3.236). Dividend Yield (0.002) settles around the average of (0.015) among similar stocks. P/S Ratio (1.069) is also within normal values, averaging (74.759).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Dividends

BAX is expected to pay dividends on October 01, 2026

Baxter International BAX Stock Dividends
A dividend of $0.01 per share will be paid with a record date of October 01, 2026, and an ex-dividend date of August 28, 2026. The last dividend of $0.01 was paid on July 01. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.43B. The market cap for tickers in the group ranges from 126 to 130.41B. ISRG holds the highest valuation in this group at 130.41B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -4%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 13%. NEPH experienced the highest price growth at 10%, while COO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 60
Price Growth Rating: 54
SMR Rating: 81
Profit Risk Rating: 95
Seasonality Score: -49 (-100 ... +100)
View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices

Industry PharmaceuticalsOther

Profile
Details
Industry
Medical Specialties
Address
One Baxter Parkway
Phone
+1 224 948-2000
Employees
37500
Web
https://www.baxter.com